Document Detail

Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
MedLine Citation:
PMID:  16388361     Owner:  NLM     Status:  MEDLINE    
Relapsing-remitting multiple sclerosis (MS) has a very fluctuating course and responsiveness to interferon beta (IFN-beta) treatment in each patient is extremely difficult. Agreement exists about the negative role of neutralising antibodies (NAbs) on clinical efficacy and markers of IFN-beta bioavailability have been studied; no guidelines exist yet about what to do when a patient becomes NAbs positive or IFN biological activity is lost. In this study 405 MS patients have been longitudinally studied for NAbs and MxA expression. A spontaneous disappearance of NAbs was observed in a few patients with low antibody titre; according to the clinical course, a therapeutic modification has been made in patients persistently NAbs positive; in these patients NAbs persisted over time despite the interruption of IFN therapy.
S Malucchi; M Capobianco; F Gilli; F Marnetto; M Caldano; A Sala; A Bertolotto
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology     Volume:  26 Suppl 4     ISSN:  1590-1874     ISO Abbreviation:  Neurol. Sci.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2006-01-02     Completed Date:  2006-07-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100959175     Medline TA:  Neurol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  S213-4     Citation Subset:  IM    
Centro Riferimento Regionale Sclerosi Multipla, CReSM, & Neurobiologia Clinica, Ospedale Universitario S. Luigi, Regione Gonzole 10, I-10043 Orbassano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / pharmacokinetics,  therapeutic use
Antibodies / blood*,  genetics
Antibody Formation
Antibody Specificity
Biological Availability
GTP-Binding Proteins / blood*,  genetics
Interferon-beta / immunology*,  pharmacokinetics,  therapeutic use
Longitudinal Studies
Multiple Sclerosis, Relapsing-Remitting / blood,  diagnosis*,  drug therapy,  immunology*
RNA, Messenger / analysis
Treatment Outcome
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Antibodies; 0/RNA, Messenger; 0/myxovirus resistance proteins; 77238-31-4/Interferon-beta; EC 3.6.1.-/GTP-Binding Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple sclerosis patients and immunomodulation therapies: the potential role of new MRI techniques...
Next Document:  Immunological markers in multiple sclerosis: tackling the missing elements.